OncoHost, a technology company focused on precision medicine, announced on Monday that the Business Intelligence Group has named OncoHost as a winner in the 2026 BIG Innovation Awards in the Health category.
Additionally, OncoHost was selected as a Top 10 Innovator – Small Business, reflecting the company's leadership in developing clinically impactful technologies.
OncoHost was recognised for its PROphet platform, an AI-driven plasma-proteomics solution designed to help oncologists predict clinical benefit and therapy-related toxicity from a single pre-treatment blood test. Its first commercial offering, PROphetNSCLC, guides first-line immunotherapy decision-making in metastatic non-small cell lung cancer (NSCLC) by revealing host-response insights that extend beyond tumour-only biomarkers.
The BIG Innovation Awards are designed to honour organisations, products, and leaders transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.
Insilico Medicine names new vice president, Clinical Development – Oncology
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Delonix Bioworks gets IND clearance for DX-104 in China
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Hologic receives FDA approval for Aptima HPV assay as primary screening option
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer